What Research Bridge Partners does

Research Bridge Partners is a 501(c)(3) nonprofit venture philanthropy organization founded in 2017 in Austin, Texas, by Isaac Barchas (former leader of the University of Texas at Austin's technology incubator) and Reid Hoffman (Partner at Greylock Partners). The firm develops and launches biomedical startup companies based on research breakthroughs from preeminent principal investigators at mid-continent US research universities, addressing a geographic mismatch in which roughly 75% of federal research funding flows to institutions outside California, Massachusetts, and New York, while nearly 80% of venture investment concentrates in those three states.

The firm's operating model rests on a proprietary data analytics platform that scores more than 75,000 principal investigators across over 100 universities using publicly available publication, citation, and collaboration data. The system identifies researchers whose publication velocity, unconventionality of science, and ecosystem characteristics signal the entrepreneurial mindset typical of successful biomedical founders. RBP then directly engages selected investigators to validate intellectual property, establish governance and board composition, build regulatory and capital strategies, and deploy formative seed capital through two complementary funds: a tax-exempt Program-Related Investment (PRI) seed fund and a for-profit venture fund that targets downstream institutional investors, family offices, and philanthropic foundations.

RBP's revenue mechanics derive from management and performance economics on these two funds plus bespoke advisory engagements with university technology transfer offices (notably with UT Southwestern and Lyda Hill Philanthropies). The team of fewer than ten professionals operates as a national sourcing and company-building platform rather than a traditional venture fund, with disclosed portfolio activity spanning Novosteo, Eradivir, Erisyon, Asalyxa Bio, MorphImmune, GenrAb, and Tetricus Labs, plus a Damon Runyon Cancer Research Foundation collaboration extending foundation capital partnerships. Pricing, fund terms, and financial statements are not publicly disclosed.

Name

Research Bridge Partners

Legal name

Research Bridge Partners

Website

https://researchbridgepartners.org

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Research Bridge Partners is a 501(c)(3) venture philanthropy firm that uses proprietary analytics to identify preeminent biomedical researchers at mid-continent US universities and provides seed capital, governance, and commercialization infrastructure to spin out startups connecting them to coastal investor ecosystems.

Ownership category

akta.pro rank

Product category

Venture Philanthropy / Biomedical Seed Investment

NAICS

Grantmaking Foundations (813211), Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Research & Science Grantmaking Foundations (BPAGAKAI)

Keywords

• Venture philanthropy
• Biomedical seed investing
• University spinouts
• Research commercialization
• Principal investigator analytics

Headquarters

HQ city

Austin

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Program-Related Investments (PRI) - Not-for-Profit Capital: Tax-exempt capital that identifies overlooked, high-quality scientific research at mid-continent universities, readies them to be launched as successful startups, and makes program-related investments in early-stage startups when commercial capital is not available. Returns are below-market but recycled for charitable purposes.
2. For-Profit Venture Capital Investments: For-profit capital that builds on the strong foundation established by PRI capital, attracting other investment dollars. Targets gains on par with leading biomedical funds for downstream investors including institutional investors, family offices, and philanthropic foundations. Deployed for seed and scaling investments in portfolio companies.
3. Partnership and Advisory Services: Bespoke high-impact advisory sessions and ad hoc strategic support for early-stage researchers and universities, including development of IP, regulatory, business development and product strategies. Provided in conjunction with partners such as Lyda Hill Philanthropies and UT Southwestern.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Research Bridge Partners is a 501(c)(3) venture philanthropy organization that makes formative seed investments in biomedical startup companies sourced from preeminent researchers at mid-continent research universities. The firm uses proprietary data analytics to identify academic principal investigators whose science and entrepreneurial mindsets are characteristic of successful biomedical startups, then provides seed capital, IP validation, governance frameworks, board-building, and business infrastructure support. It operates two complementary capital structures—a tax-exempt program-related investment (PRI) seed fund and a for-profit venture fund—to bridge mid-continent university research with coastal commercialization ecosystems in the Bay Area and Boston.

Product overview

Research Bridge Partners is a 501(c)(3) venture philanthropy and investment organization, not a technology product company. It does not offer a traditional software platform, SaaS product, or API. The organization's core offering is its proprietary data analytics service for identifying preeminent academic researchers with commercialization potential, combined with seed capital investments, mentorship programs, and strategic support services for university spinouts. The company uses its proprietary algorithms and statistical models (proprietary analytics) as its primary analytical tool, coupled with direct engagement and support for researchers to help them become scientific co-founders of successful biomedical startups.

Differentiator

Problem solved

Functional benefit

Products and services

• PRI Seed Fund (Program-Related Investment Fund)
• For-Profit Venture Fund
• Partnership and Advisory Services

Quantifiable outcome

• Heartland startups receive approximately 33% of the capital and 60% of the valuation of Boston biomedical startups, indicating structural undercapitalization that RBP addresses.
• +2 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Damon Runyon Cancer Research FoundationcoreStrategic or Co-development PartnerCollaboration to cultivate financial support of Damon Runyon Cancer Research Foundation grantees and funded projects as they approach commercialization. RBP's CEO Lydia McClure oversaw this collaboration prior to becoming CEO.
• UT Southwestern Medical CentercoreStrategic or Co-development PartnerPrimary research institution partner where RBP and Lyda Hill Philanthropies deploy capital to identify researchers, establish governance structures, safeguard IP, and recruit board members and senior executives for spinouts. UT Southwestern is ranked #1 globally among healthcare institutions for publishing high-quality scientific research and leads approximately 5,800 research projects with nearly $634 million in NIH and other support.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Petri: Boston-based biotech startup accelerator providing seed funding and support for early-stage life sciences founders. Comparable as an early-stage biotech formation platform, though it operates in the coastal commercialization ecosystem RBP targets.
• BioGenerator: St. Louis-based nonprofit that creates and funds startup companies from local university research, including bioscience. Directly comparable as a regional biomedical venture philanthropy and incubator operating outside coastal hubs with a formative-investment model.
• MBC BioLabs: San Francisco-based biotech startup incubator providing lab space, equipment, and seed support to early-stage life sciences companies. Comparable as an early-stage biotech founder-support organization, though geographically focused on a coastal ecosystem.

Broad incumbents

• IndieBio (SOSV): Global biotech accelerator that provides seed funding and lab infrastructure to early-stage biology startups. Comparable as an early-stage biotech formation platform, though operating at broader global scale and with traditional venture returns expectations.
• Wellcome Leap: Philanthropy-funded organization that builds and funds breakthrough health research programs at scale. Comparable as a large-scale philanthropic capital allocator focused on translating breakthrough biomedical science into impact.
• ARCH Venture Partners: Established early-stage deep-tech and life sciences venture firm with deep ties to university research. Comparable in its university-research focus and formative-investment approach, but operates at significantly larger fund scale and broader geography.
• Howard Hughes Medical Institute (HHMI): Major biomedical research organization that funds and operates research labs at universities, with growing investment activity in translational science. Comparable as a mission-driven biomedical research and commercialization actor with philanthropic capital.
• F-Prime Capital: Healthcare and technology venture firm with ties to Fidelity that invests across the life sciences continuum. Comparable as a mission-driven life sciences investor supporting biomedical innovation from research to commercialization.

Regional players

• Purdue Foundry: Purdue University's technology transfer and startup accelerator that commercializes Purdue-affiliated research. Comparable as a university-based commercialization entity, though RBP's portfolio has sourced heavily from Purdue innovations.
• BioCrossroads: Indiana-based life sciences investment and development organization that invests in and supports biomedical startups from Indiana research institutions. Directly comparable as a regional venture philanthropy player operating in RBP's heartland thesis geography.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/research-bridge-partners

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments4 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Research Bridge Partners